ClinConnect ClinConnect Logo
Search / Trial NCT06215157

A Comparison of Stroke Volume Variation for Prediction of Fluid Responsiveness

Launched by RENJI HOSPITAL · Jan 10, 2024

Trial Information

Current as of July 23, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is studying two different methods of monitoring how well a patient's heart is pumping blood, specifically looking at something called stroke volume variation (SVV). This measurement helps doctors determine if a patient needs more fluids during surgery. The trial will compare the traditional FloTrac system, which involves inserting a device into the body, with a new, non-invasive method called transthoracic electrical bioimpedance (BioZ.com™), which uses electrodes placed on the skin to gather the same information without needing any invasive procedures.

To be eligible for this trial, participants should be between 18 to 65 years old, undergoing laparoscopic surgery for gastrointestinal tumors while under general anesthesia, and have a body mass index (BMI) between 18 and 30. Participants will need to provide consent and cannot have certain heart or liver conditions, severe heart failure, or other specified health issues. Those who join the study can expect to have their heart function monitored using both methods at the same time during their surgery. This research is important because it could help improve how doctors assess fluid needs during surgery, potentially leading to better patient outcomes.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age 18≤ Age ≤65
  • patients undergoinglaparoscopic elective surgery for gastrointestinal tumors under general anesthesia
  • 18 kg/m2≤BMI≤30 kg/m2
  • ASA classification I-III
  • Patients signed informed consent form
  • Exclusion Criteria:
  • Arrhythmias
  • The patient is diagnosed with severe cardiovascular disease(pulmonary arterial hypertension、left ventricular ejection fraction\< 50%、aortic aneurysm、extensive peripheral arterial occlusive disease,、significant valvulopathy)
  • Severe heart failure (METS\<4)
  • The patient is diagnosed with severe hepatic dysfunction (ChildePugh class C)
  • The patient is diagnosed with severe renal dysfunction (undergoing dialysis before surgery)
  • There is an infectious lesion on the skin or subcutaneous tissue where the non-invasive electrode piece is placed
  • History of allergy to anesthetic drugs
  • Weight\<40kg
  • Allergies to 6% hydroxyethyl starch, Fresenius Kabi, Deutschland

About Renji Hospital

Renji Hospital, a prestigious medical institution affiliated with Shanghai Jiao Tong University School of Medicine, is dedicated to advancing healthcare through innovative clinical research. With a strong emphasis on patient-centered care, Renji Hospital conducts a wide range of clinical trials across various therapeutic areas, harnessing cutting-edge technology and evidence-based practices. The hospital's multidisciplinary team of experienced researchers and medical professionals collaborates closely to ensure rigorous study design and execution, aiming to contribute significantly to medical knowledge and improve treatment outcomes for patients worldwide.

Locations

Pudong, Shanghai, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported